A new book by Charles Piller raises questions about the safety of simufilam, a drug that was touted as a potential cure for dementia. The 73-year-old study participant, Stephen Price, had struggled with minor forgetfulness and memory loss, which worsened over time. His son, Matthew, an epidemiologist, enrolled him in a study using simufilam, hoping it would slow or reverse cognitive decline.
Piller’s book, “Doctored,” reveals that the drug was developed by Cassava Sciences, a company with a history of failed drugs. The development team created simufilam as a way to address the FDA’s rejection of another product. However, neuroscientist Matthew Schrag questioned some aspects of the study, suspecting possible issues with the research.
Piller, a scientific investigative journalist, spent years researching this story and became “obsessed” with uncovering the truth. The book delves into the complexities of dementia research and raises concerns about the development process. Experts warn that cases of dementia will nearly double in the next 25 years, making the search for a cure more urgent.
While Piller’s book provides valuable insights, it may be challenging to read due to its technical nature. However, for those with a background in Alzheimer’s research or healthcare, “Doctored” offers essential information and raises important questions about the safety of simufilam.
Source: https://tricountyreporter.com/stories/doctored-fraud-arrogance-and-tragedy-in-the-quest-to-cure-alzheimers,58899